



**Figure S1.** Subgroup analysis. \*Fully-adjusted for age; sex, BMI; SBP; the alcohol consumption frequency; the income status; comorbidities, including diabetes, heart failure, and chronic obstructive pulmonary disease; and each antihypertensive medication use. Square boxes indicate the hazard ratio and horizontal bars indicate 95% confidential intervals. BMI: body mass index; SBP: systolic blood pressure; ARB: angiotensin receptor blocker.

**Table S1.** International Classification of Disease (10th edition) Clinical Modification (ICD 10-CM) codes used to define the study population, outcomes, and comorbidities.

Diseases	ICD-10 Codes	Diagnosis Definition
Essential hypertension	I10–I13	Essential hypertension
		I10: essential (primary) hypertension
		I11: hypertensive heart disease
		I12: hypertensive chronic kidney disease
		I13: hypertensive heart and chronic kidney disease
Overall cancer	C00–C96	Site-specific cancer
		C34: lung cancer
		C18–C20: colorectal cancer
		C50: breast cancer
		C61: prostate cancer
		C67: bladder cancer
		C25: pancreatic cancer
		C64: kidney cancer
		C22: hepatic cancer
C16: gastric cancer		
Diabetes	E10–E13	E10: type 1 diabetes mellitus
		E11: type 2 diabetes mellitus
		E12: malnutrition-related diabetes mellitus
		E13: other specified diabetes mellitus
Heart failure	I509	I509: heart failure, unspecified
Chronic obstructive lung disease	J449	J449: chronic obstructive pulmonary disease, unspecified

**Table S2.** Comparison of baseline characteristics of individuals with and without an incident of cancer during the follow-up period.

<b>Variable</b>	<b>All Patients (N = 70,549)</b>	<b>Without Cancer (N = 66,036)</b>	<b>With Cancer (N = 4513)</b>	<b>p value</b>
Follow-up, years	8.6 (6.7–10.8)	8.8 (6.9–10.9)	4.8 (2.6–7.3)	<0.0001
Death, N (%)	3025 (4.3)	1796 (2.7)	1229 (27.2)	<0.0001
Age, years	55.2 ± 9.2	55.0 ± 9.1	58.9 ± 9.0	0.3819
Male sex, N (%)	42,990 (60.9)	40,065 (60.7)	2925 (64.8)	<0.0001
BMI, kg/m <sup>2</sup>	24.9 ± 3.0	24.9 ± 3.0	24.7 ± 3.0	0.3575
SBP, mmHg	139.7 ± 18.3	139.7 ± 18.3	140.1 ± 19.0	0.0001
Smoking, N (%)				0.0235
Current	16,214 (23.0)	15,105 (22.9)	1109 (24.6)	
Past smoker	12,155 (17.2)	11,412 (17.3)	743 (16.5)	
Never-smoker	42,180 (59.8)	39,519 (59.8)	2661 (59.0)	
Alcohol, N (%)				<0.0001
None	35,575 (50.4)	33,217 (50.3)	2358 (52.3)	
1–2/week	22,265 (31.6)	20,967 (31.8)	1298 (28.8)	
3–4/week	8302 (11.8)	7810 (11.8)	492 (10.9)	
≥5/week	4407 (6.3)	4042 (6.1)	365 (8.1)	
Income, N (%)				0.742
Low (1–3 decile)	17,221 (24.4)	16,113 (24.4)	1108 (24.6)	
Middle (4–7 decile)	23,982 (34.0)	22,430 (34.0)	1552 (34.4)	
High (7–10 decile)	29,346 (41.6)	27,493 (41.6)	1853 (41.1)	
Comorbidities				
Diabetes, N (%)	13,382 (19.0)	12,439 (18.8)	943 (20.9)	0.0006
Heart failure, N (%)	216 (0.3)	199 (0.3)	17 (0.4)	0.3755
COPD, N (%)	1704 (2.4)	1539 (2.3)	165 (3.7)	<0.0001
Use of antihypertensive drugs				
ACEI, N (%)	4210 (6.0)	3848 (5.8)	362 (8.0)	<0.0001
ARB, N (%)	55,645 (78.9)	52,351 (79.3)	3294 (73.0)	<0.0001
BB, N (%)	13,158 (18.7)	12,176 (18.4)	982 (21.8)	<0.0001
CCB, N (%)	51,036 (72.3)	47,593 (72.1)	3443 (76.3)	<0.0001
Diuretics, N (%)	32,990 (46.8)	30,835 (46.7)	2155 (47.8)	0.1687

BMI, body mass index; SBP, systolic blood pressure; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BB, beta blocker; CCB, calcium channel blocker.